Annovis Bio
Tracked across 2 events · 15 articles · First seen Mar 19, 2026 · Last active Apr 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Annovis Bio announced a partnership with NeuroRPM to integrate an FDA-cleared AI platform into its Parkinson's disease study. This collaboration is expected to enhance data collection and monitoring of disease progression, potentially strengthening the evidence base for its drug candidate, buntanetap.
Mar 19, 2026 · 7 articles
Tech
Annovis Bio announced the issuance of a U.S. patent for its investigational oral therapy, buntanetap, covering the prevention and treatment of neurological injuries from brain infections. This patent strengthens Annovis Bio's intellectual property estate and extends protection through 2044, potentially increasing the market value and future revenue streams for the company.
Apr 02, 2026 · 8 articles
NeuroRPM
partner
↔
Annovis Bio
Annovis Bio and NeuroRPM are partners in a clinical study for Parkinson's diseas
Cheng Fang
Senior Vice President, Research and Development
↔
Annovis Bio
Cheng Fang is the Senior Vice President of Research and Development at Annovis B
NEWSDESK
Track Annovis Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard